| Stereochemistry | RACEMIC |
| Molecular Formula | C26H28Cl2N4O4 |
| Molecular Weight | 531.431 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@@](CN4C=CN=C4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2
InChI
InChIKey=XMAYWYJOQHXEEK-BVAGGSTKSA-N
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26+/m1/s1
trans-Ketoconazole was identified as impurity of an antifungal compound cis-ketoconazole. Cis-Ketoconazole displayed broad-spectrum in vivo activity in a wide range of experimental fungal infections caused by different fungi in a variety of animal models. trans-isomer of ketoconazole is less active than cis-ketoconazole.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 38.3 µM [IC50] | |||
| 6.57 µM [IC50] | |||
| 0.897 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
AZ-AHR cells were incubated for 24 h with tested compound (trans-Ketoconazole ), TCDD (5 nM) and/or vehicle (DMSO; 0.1% v/v). After the treatments, cells were lysed and luciferase activity was measured. Dose– response curve fittings and calculations of half-maximal effective concentrations (EC50) and half-maximal inhibitory concentrations (IC50) were performed using GraphPad Prism 5 software (GraphPad Software, San Diego, USA). In parallel, cell viability was determined by conventional MTT test.
SUBSTANCE RECORD
